Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
MarketWatch on MSN10d
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds — and she’s not aloneTori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback